Last reviewed · How we verify
Regranex (BECAPLERMIN)
At a glance
| Generic name | BECAPLERMIN |
|---|---|
| Sponsor | Omj Pharmaceuticals |
| Drug class | Human Platelet-derived Growth Factor |
| Target | Platelet-derived growth factor receptor |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Neuropathic diabetic ulcer - foot
Common side effects
- Erythematous rashes
- Burning sensation at application site
- Erythema at application site
Serious adverse events
- Cancer (systemic malignancies)
- Death from systemic malignancies
Key clinical trials
- Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction (PHASE2)
- Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing (PHASE2)
- Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor (NA)
- Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
- Fatty Liver and Pancreatic Steatosis
- Collagen Matrix + rhPDGF-BB vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences (NA)
- Reconstructive Therapy of Peri-implantitis with PDGF-BB (Gem-21) (PHASE4)
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |